Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system

被引:79
作者
He, Yupeng [1 ]
King, Martin S. [1 ]
Kempf, Dale J. [1 ]
Lu, Liangjun [1 ]
Ben Lim, Hock [1 ]
Krishnan, Preethi [1 ]
Kati, Warren [1 ]
Middleton, Timothy [1 ]
Molla, Akhteruzzaman [1 ]
机构
[1] Abbott Labs, Global Pharmaceut Res & Dev, Abbott Pk, IL 60064 USA
关键词
D O I
10.1128/AAC.01149-07
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We characterized the selective advantage profiles of a panel of hepatitis C virus (HCV) NS3 protease mutants with three HCV protease inhibitors (PIs), BILN-2061, ITMN-191, and VX-950, using a genotype 1b HCV replicon system. Selective advantage curves were generated by a novel mathematical method that factors in the degree of drug susceptibility provided by the mutation, the base-level replication capacity of the mutant in the absence of drugs, and the overall viral replication levels as a function of drug concentration. Most of the mutants showed significantly increased selective advantages over the wild-type species upon drug treatment. Each drug is associated with unique selective advantage profiles that reflect its antiviral activity and mutant susceptibility. Five mutants (R155K/Q, A156T, and D168A/V) showed significant levels of selective advantage after treatment with >10 nM (similar to 7 times the wild-type 50% effective concentration [EC50]) of BILN-2061. R155K displayed dominant levels of selective advantage over the other mutants upon treatment with ITMN-191 over a broad range of concentrations. Upon VX-950 treatment, various mutants (A156T, A156S, R155K, T54A, V170A, V36M/RI55K, and R155Q) exhibited high levels of selective advantage in different drug concentration ranges, with A156T and A156S being the dominant mutants at >3 mu M (similar to 10 times the wild-type EC50) of VX-950. This method provides more accurate estimates of the behavior of various mutants under drug pressure than replication capacity analysis. We noted that the R155K mutant shows reduced susceptibility to all three PIs and significant selective advantage, raising concern over the potential emergence of R155K as a multidrug-resistant, highly fit mutant in HCV patients treated with PIs.
引用
收藏
页码:1101 / 1110
页数:10
相关论文
共 29 条
  • [1] Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model
    Chen, Chih-Ming
    He, Yupeng
    Lu, Liangjun
    Ben Lim, Hock
    Tripathi, Rakesh L.
    Middleton, Tim
    Hernandez, Lisa E.
    Beno, David W. A.
    Long, Michelle A.
    Kati, Warren M.
    Bosse, Todd D.
    Larson, Daniel P.
    Wagner, Rolf
    Lanford, Robert E.
    Kohlbrenner, William E.
    Kempf, Dale J.
    Pilot-Matias, Tami J.
    Molla, Akhteruzzaman
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (12) : 4290 - 4296
  • [2] Courcambeck J, 2006, ANTIVIR THER, V11, P847
  • [3] Cell culture and infection system for hepatitis C virus
    Kato, Takanobu
    Date, Tomoko
    Murayama, Asako
    Morikawa, Kenichi
    Akazawa, Daisuke
    Wakita, Takaji
    [J]. NATURE PROTOCOLS, 2006, 1 (05) : 2334 - 2339
  • [4] An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus
    Lamarre, D
    Anderson, PC
    Bailey, M
    Beaulieu, P
    Bolger, G
    Bonneau, P
    Bös, M
    Cameron, DR
    Cartier, M
    Cordingley, MG
    Faucher, AM
    Goudreau, N
    Kawai, SH
    Kukolj, G
    Lagacé, L
    LaPlante, SR
    Narjes, H
    Poupart, MA
    Rancourt, J
    Sentjens, RE
    St George, R
    Simoneau, B
    Steinmann, G
    Thibeault, D
    Tsantrizos, YS
    Weldon, SM
    Yong, CL
    Llinàs-Brunet, M
    [J]. NATURE, 2003, 426 (6963) : 186 - 189
  • [5] In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061 - Structural analysis indicates different resistance mechanisms
    Lin, C
    Lin, K
    Luong, YP
    Rao, BG
    Wei, YY
    Brennan, DL
    Fulghum, JR
    Hsiao, HM
    Ma, S
    Maxwell, JP
    Cottrell, KM
    Perni, RB
    Gates, CA
    Kwong, AD
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (17) : 17508 - 17514
  • [6] In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061
    Lin, C
    Gates, CA
    Rao, BG
    Brennan, DL
    Fulghum, JR
    Luong, YP
    Frantz, JD
    Lin, K
    Ma, S
    Wei, YY
    Perni, RB
    Kwong, AD
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (44) : 36784 - 36791
  • [7] Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro
    Lu, LJ
    Pilot-Matias, TJ
    Stewart, KD
    Randolph, JT
    Pithawalla, R
    He, WP
    Huang, PP
    Klein, LL
    Mo, HM
    Molla, A
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (06) : 2260 - 2266
  • [8] Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay
    Ludmerer, SW
    Graham, DJ
    Boots, E
    Murray, EM
    Simcoe, A
    Markel, EJ
    Grobler, JA
    Flores, OA
    Olsen, DB
    Hazuda, DJ
    LaFemina, RL
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (05) : 2059 - 2069
  • [9] Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: Virus fitness in the absence and in the presence of drug
    Mammano, F
    Trouplin, V
    Zennou, V
    Clavel, F
    [J]. JOURNAL OF VIROLOGY, 2000, 74 (18) : 8524 - 8531
  • [10] Treating viral hepatitis C: Efficacy, side effects, and complications
    Manns, M. P.
    Wedemeyer, H.
    Cornberg, M.
    [J]. GUT, 2006, 55 (09) : 1350 - 1359